Biomica is a clinical-stage biopharmaceutical company dedicated to developing innovative microbiome-based therapeutics for the treatment of cancer, immune-mediated, and infectious diseases. Synergizing proprietary big data and computational capabilities, Biomica develops best-in-class therapeutics to address high-value, unmet medical needs.
Our unique approach is focused on understanding the functional elements of the microbiome. This enables us to select a minimal number of desired microbial candidates, thereby maximizing beneficial effects while minimizing potential adverse effects through carefully curated consortia.
Our drug candidates have been identified and designed using PRISM, a proprietary cutting-edge computational platform that integrates advanced AI capabilities, ‘Big Data’, and a comprehensive proprietary database. Through metagenomics sequencing, Biomica gains deeper insights into the microbiome, employing high-resolution taxonomy and functional profiling of the human microbiome. These insights enable us to develop novel solutions for complex host-microbiome interrelations and make clinically relevant predictions.
Biomica will be attending Bio Europe conference, and we’re looking forward to connecting with industry leaders and innovators. Our CEO, Dr. Elran Haber, and VP of Business Development, Mel Larrosa, will be available for meetings.
Dr. Elran Haber, CEO of Biomica, will be participating as a panelist at the 9th Microbiome Movement – Drug Development Summit. On July 12th at 9:30 am ET, Dr. Haber will engage in the panel discussion “Defining Innovative Clinical Strategies Conserving Spend.” This discussion will explore adaptive trial methodologies, strategic partnerships, and criteria for attracting […]
